Pharmaceutical marketing is the most heavily governed commercial communication there is. Promotional material passes a medical, legal and regulatory review before it exists publicly; any claim about a product carries obligations about balance and safety information; and anything that looks like a report of a side effect has to be routed to the company's safety function within a set time. An agency that treats those as constraints on the work has misunderstood: they are the work.
The review committee is the schedule
Medical, legal and regulatory review is a real process with real queues, and elapsed time is usually several multiples of production time. Plans that budget for design and copy and not for review slip every cycle, and the slippage gets blamed on whoever is least able to defend themselves. Name the reviewers, agree turnarounds, submit in batches, and treat the queue as a fixed dependency.
Every product claim carries balance and safety obligations
Promotional material that makes a claim about a product carries requirements about presenting risk information alongside benefit, and about the accompanying prescribing information. That shapes the design, not just the copy: the space, the prominence and the placement have to be planned from the first layout. Agencies new to the sector reliably discover this after the design is approved internally.
Adverse event reporting applies to everything you run
If a comment, a message, a form or a call center transcript describes a possible side effect, it has to reach the company's pharmacovigilance function inside a defined window. That means every channel you open, including social and any comment field, comes with a monitoring and escalation obligation. Open none of them without deciding who watches, how often, and what they do.
Unbranded disease education is a different set of rules
Material about a condition that does not name or imply a product is governed differently from promotional material, and it is where a great deal of legitimate and useful pharmaceutical publishing happens. The line between the two is narrower than it looks and is a regulatory judgement rather than a marketing one. Decide which side each asset is on before it is written.
Professional and patient audiences have different rules
What may be said to a prescriber and what may be said to a patient differ, sometimes substantially and always by jurisdiction, and the same asset cannot serve both. Gate the professional material properly, keep the audiences separate in targeting, and make sure the agency knows which audience each deliverable is for before it starts.
Questions people ask about pharma digital agency
Why do pharmaceutical campaigns take so long?
Because medical, legal and regulatory review sits between production and publication, and elapsed review time is usually several times production time. Plans that do not budget for it slip every cycle.
Can we run social media for a prescription product?
Only with a monitoring and escalation process, because any comment describing a possible side effect has to reach pharmacovigilance within a defined window. Open no channel without deciding who watches it.
What is unbranded disease education?
Material about a condition that does not name or imply a product. It is governed differently from promotional material and is where much legitimate publishing happens, but the line is a regulatory judgement.
Can one asset serve doctors and patients?
No. What may be said to a prescriber and to a patient differ by audience and by jurisdiction. Keep the audiences separate in targeting and decide which one each deliverable is for before it is written.